InvestSMART

Firebrick Pharma Limited (ASX:FRE)

ALERT: Price-sensitive ASX Announcement for FRE
Current share price for FRE : $0.037 -0.025 (-40.32%)+
Announcement
Release
21 Apr 2026 4:50PM
Price at Release
$0.062
Full Release
download
Summary
Firebrick Pharma Limited's March 2026 Quarterly Activity Report highlights several key developments and financial updates. The company reported a notable increase in cash sales, attributed primarily to growth in the US market. Nasodine Nasal Spray received approval in Indonesia, and the Nasodine Throat Spray was launched in Singapore and Fiji. Strategic appointments were made to support global expansion, and a successful capital raise of $1.5 million was completed to secure operational funding for the upcoming year. Despite increased operating expenses due to specific initiatives, the company anticipates a stabilization of costs in the following quarter.
Key Points
  • Nasodine Nasal Spray approved in Indonesia.
  • Launch of Nasodine Throat Spray in Singapore and Fiji.
  • Significant growth in US sales leading to a 105% increase in cash sales.
  • Strategic appointments to support international expansion.
  • Successful $1.5 million capital raise via private placement.
  • Operating expenses increased due to regulatory and business development costs.
  • Expected stabilization of expenses in the next quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.